Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes
about
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoproteinAdenoviral vectors as novel vaccines for influenza.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responsesSynergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.The influence of delivery vectors on HIV vaccine efficacyAdenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsNew candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Genetic medicine strategies to protect against bioterrorism.Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primatesChimpanzee adenovirus antibodies in humans, sub-Saharan Africa.Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.New prospects for a preventive HIV-1 vaccine.Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.Development of nonhuman adenoviruses as vaccine vectors.Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections.Pre-erythrocytic malaria vaccines: towards greater efficacy.Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron AHexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.Viral vector vaccines make memory T cells against malaria.STEP trial and HIV-1 vaccines inducing T-cell responses.Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimensTherapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.Chimpanzee-origin adenovirus vectors as vaccine carriers.Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
P2860
Q30363661-6B78ECA1-B7B1-493F-B16C-3B2933E4FBD6Q30370445-C54E45EE-84DF-498F-A14F-BF3419364F48Q30378897-49EF5E72-CDC9-4793-BE38-4EA4B74C18C3Q33320536-90D8E3DC-6829-462C-9BA8-EAC3DE567BE5Q33557760-9F6A06C2-B26E-4AC0-968B-DD7059159B0BQ33798772-FB7A7441-30C4-4A68-870F-0D6FC3EBF599Q34033557-10AA9B94-79E8-463C-B30B-C65AED301823Q34077543-B8222139-8060-4DE5-9796-EE1C1C4C9964Q34178208-11650EB0-A2A7-44A6-AD4E-FC482DD973ABQ34204440-324120EC-B0E8-4584-A1FA-CE2DAACFFF74Q34290768-3D38ECFC-1CAA-45E9-A2B8-EB47E705709EQ34334441-E5F8B713-2B74-457A-88BD-4F2AC086E68BQ34701517-25084FA9-0B1E-498D-AC73-C2FB56DD5279Q34767181-AEA0C802-1C4F-45BA-BACD-D88667406612Q35159523-AD695FF6-34B1-460B-8FB5-ED8BB29008CCQ35344875-A31202D2-4839-4EA4-9B29-0F4CD69AF031Q35568563-24B2A3B9-BC5B-4FAB-93CC-EDD8311BDA56Q35792153-96F7F0DE-C92C-47AA-84B8-7133B880CAA6Q35857215-5864853C-7F5E-4220-8BB6-8D79120BE761Q35990696-1172A0F9-FD6F-4DE2-BBFE-79F81C5BE207Q36166161-15A83988-5AA6-4BA8-8C20-20847D2BC54EQ36223864-8BCB081D-FB01-4D0B-A37A-7D5D98F01E92Q36315185-91F27DAC-509C-4428-A202-0442BDDAB6FBQ36317264-2D0E59B8-7112-4FCC-8C03-7C6DE201D9FBQ36349567-A0D5EB35-81E6-4E9B-AD3A-34AA051319C6Q36403400-A25519AB-D400-44BD-BB6A-3434B4FD15BCQ36463070-02D67533-6218-48B6-8F8E-8A964E5809B7Q36540068-ECD6C86B-E565-4AE8-9B96-66B6ECE730DFQ36659279-F78B5685-2FC4-4F1B-BDF0-F6ACBC60A011Q36802741-ADBB683F-009D-4FF7-A568-D2FAEF410B14Q37130450-CA463502-6099-404A-9C33-577A33419517Q37263878-AA49E850-C6DC-4910-884B-B4DC7DD6ED18Q37336847-FC8FBAC2-106C-4C13-8ACE-8DEFE3A0F7BCQ37461371-6B4566EF-F0F3-4086-8973-EB59126EF838Q37713951-82A2AEF0-FBED-49E3-8196-05F2D963D105Q37715148-2537C75F-025A-4BF1-9BE7-DE012671D84DQ38096490-F5155232-EC5B-41CA-A537-06CE5F6876EBQ40333540-9C7DF3A9-A650-45D8-BCD6-347601ED2444Q40345527-EBDF95BC-2D3E-4166-93A8-47688F6C6627Q42064105-51DA88EA-3CC2-472A-91BB-16BB3D4BCAE0
P2860
Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Human immunodeficiency virus t ...... of human and simian serotypes
@ast
Human immunodeficiency virus t ...... of human and simian serotypes
@en
type
label
Human immunodeficiency virus t ...... of human and simian serotypes
@ast
Human immunodeficiency virus t ...... of human and simian serotypes
@en
prefLabel
Human immunodeficiency virus t ...... of human and simian serotypes
@ast
Human immunodeficiency virus t ...... of human and simian serotypes
@en
P2093
P2860
P50
P1433
P1476
Human immunodeficiency virus t ...... of human and simian serotypes
@en
P2093
P2860
P304
P356
10.1128/JVI.78.14.7392-7399.2004
P407
P577
2004-07-01T00:00:00Z